Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

349 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-26

Study Completion Date

2022-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, parallel dose assigned, double blind, multi center, Phase II study assessing the efficacy, safety, and immunogenicity of VLP vaccine (Authentic and Alpha variants) in adults between 18 and 59 years who are healthy or have medically stable chronic diseases and who have no known history of SARS-CoV-2 infection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults

NCT04818281

Covid19

COMPLETED PHASE1

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults

NCT04866069

Covid19

TERMINATED PHASE1

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

NCT05096845

COVID-19 Pandemic

UNKNOWN PHASE3

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

NCT04762680

COVID-19

COMPLETED PHASE2/PHASE3

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

NCT05472038

SARS-CoV-2 Infection COVID-19

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to evaluate the humoral and cellular immune response of VLP vaccine candidates (harboring M, N, E, and HexaPro S antigens of the virus), as an efficacy criteria.

Approximately 330 subjects will be randomized in a 1:1:1 ratio to receive two doses of 40 mcg VLP vaccine for Wuhan (n=110) or 40 mcg VLP vaccine for Alpha (British) variant (n=110) or 40 mcg VLP vaccine for Wuhan+Alpha variant (n=110) 21 days apart.

The study will be completed in 14 months.

All injections will be done subcutaneously.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Double-blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VLP-Wuhan group (Group V1)

110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.

Group Type EXPERIMENTAL

SARS-CoV-2 VLP Vaccine-Wuhan

Intervention Type BIOLOGICAL

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

VLP-Alpha (British) variant group (Group V2)

110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.

Group Type EXPERIMENTAL

SARS-CoV-2 VLP Vaccine-Alpha (British) variant

Intervention Type BIOLOGICAL

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

VLP-Wuhan+Alpha group (Group V3)

110 participants will receive 40 mcg of Alum adsorbed VLP vaccine for Wuhan and Alpha variant adjuvanted with K3-CpGODN (1 ml), in two doses 21 days apart.

Initial vaccination with Wuhan followed by a booster of Alpha variant.

Group Type EXPERIMENTAL

SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant

Intervention Type BIOLOGICAL

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SARS-CoV-2 VLP Vaccine-Wuhan

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

Intervention Type BIOLOGICAL

SARS-CoV-2 VLP Vaccine-Alpha (British) variant

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus

Intervention Type BIOLOGICAL

SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant

Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Authentic VLP Vaccine Alpha Variant VLP Vaccine Combination of Authentic and Alpha VLP Vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible for the study, each participant must satisfy all the following criteria:

1. Female and/or male participant who is informed and about his/her participation and who agrees to give his/her written informed consent.
2. Aged between 18 and 59 years.
3. Negative Immunoglobulin G (IgG)/Immunoglobulin M (IgM) antibody for COVID-19.
4. Negative COVID-19 quantitative polymerase chain reaction (qPCR) test result.
5. Able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
6. Negative blood test for hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) at screening period.
7. Body temperature \< 37.2°C.
8. Body Mass Index (BMI) ranged between 18-35 kg/m2.
9. Clinical laboratory test results within the reference range of the laboratory or clinically non-significant (complete blood count (CBC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, urea, creatinine, and fasting glucose) or any laboratory parameters defined in the study protocol.
10. Good general health as determined by physical examination, laboratory screening, and review of medical history within 14 days prior to participation.
11. Female participants of childbearing potential may be enrolled in the study if the subject fulfils all the following criteria:

* Have a negative pregnancy test on the day of screening and prior to each study vaccine administration.
* Use an effective contraceptive method for at least 30 days prior to first dose of study vaccine and agree to continue using one highly effective form of birth control through 6 months after the administration of the last dose of study vaccine.
12. Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as postmenopausal (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
13. Male participants who agree to use an effective contraceptive method during the study period and until 6 months after the last dose of study vaccine.

Exclusion Criteria

Participants with any of the following criteria will be excluded:

1. History of laboratory-confirmed SARS-COV-2 infection.
2. History of seizures, encephalopathy, or psychosis.
3. Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to any vaccine or study vaccine and/or any other excipients of the vaccine.
4. Pregnant, breastfeeding or planning to become pregnant within 6 months after the study vaccine administration.
5. Suspected active infection or other acute illness, including fever \> 37.2°C.
6. Any presence of clinical relevance of cardiovascular disease (including but not limited to arrythmia, myocardial infarction, uncontrolled hypertension, coronary artery disease, or congestive heart failure).
7. Any presence of clinical relevance of serious chronic disease \[asthma, diabetes, thyroid diseases etc.).
8. Any presence of clinical relevance of congenital or acquired angioedema.
9. Diagnosis of immunodeficiency.
10. Diagnosis of bleeding diathesis.
11. Use of immunosuppressive medications, anti-allergic therapy, cytotoxic therapy, inhaler corticosteroids (excluding allergic rhinitis or topical steroid ointments).
12. Those who received blood/plasma products or immunoglobulins and/or blood transfusion within the last 6 months.
13. Those who participated in another vaccine study or received an investigational/experimental drug within 1 month prior to study entry.
14. History of any live vaccine within 1 month prior to study participation.
15. History of any inactivated vaccine within 1 month prior to study participation.
16. Use of active tuberculosis treatment.
17. According to the investigator's judgement, those who have any condition (medical, psychological, social, etc.) that may impair the subject's compliance with the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes